Volume 30, Number 3—March 2024
Research
Monitoring and Characteristics of Mpox Contacts, Virginia, USA, May–November 2022
Eleanor N. Field
, Elizabeth McCarty, Dawn Saady, and Brandy Darby
, Elizabeth McCarty, Dawn Saady, and Brandy Darby
Table 1
Characteristics of 991 persons enrolled in mpox contact tracing and symptom monitoring cohort, Virginia, USA, May 1–November 1, 2022*
| No. (%) persons |
||||
|---|---|---|---|---|
| Characteristic |
Total |
Persons without mpox |
Persons with mpox |
|
| Total |
991 | 963 | 28 | |
| Sex assigned at birth | ||||
| M | 494 (55.1) | 467 (53.7) | 27 (96.4) | |
| F | 403 (44.9) | 402 (46.3) | 1 (3.6) | |
| Missing |
94 |
94 |
0 |
|
| Age group, y | ||||
| 0–9 | 32 (3.9) | 32 (4.0) | 0 (0) | |
| 10–19 | 48 (5.8) | 48 (6.0) | 0 | |
| 20–29 | 130 (15.8) | 128 (16.1) | 2 (7.1) | |
| 30–39 | 205 (24.9) | 193 (24.2) | 12 (42.9) | |
| 40–49 | 155 (18.8) | 145 (18.2) | 10 (35.7) | |
| 50–59 | 101 (12.3) | 99 (12.4) | 2 (7.1) | |
| 60–69 | 103 (12.5) | 101 (12.7) | 2 (7.1) | |
| 70–79 | 0 (4.4) | 36 (4.5) | 0 | |
| >80 | 14 (1.7) | 14 (1.8) | 0 | |
| Missing | 167 |
167 | 0 | |
*Calculated percentages exclude missing values.
Page created: January 18, 2024
Page updated: February 22, 2024
Page reviewed: February 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.